Stereotactic body radiation therapy for primary kidney cancer

被引：0
|
作者：
Abancourt, L. [1 ]
Le Guevelou, J. [2 ]
Taillez, A. [1 ]
Vu, A. [1 ]
de Crevoisier, R. [2 ]
Supiot, S. [3 ]
Hennequin, C. [4 ]
Chapet, O. [5 ,6 ]
Blanchard, P. [7 ]
Mirabel, X. [1 ]
Lartigau, E. [1 ,8 ,9 ]
Pasquier, D. [1 ,8 ,9 ]
机构：
[1] Ctr Oscar Lambret, Dept Univ Radiotherapie, 3 Rue Frederic Combemale, Lille, France
[2] Ctr Reg Lutte Canc Eugene Marquis, Radiotherapy Dept, F-35042 Rennes, France
[3] Ctr Rene Gauducheau, Inst Cancerol Ouest, Blvd Jacques Monod, F-44805 St Herblain, France
[4] Univ Paris, Hop St Louis, Serv Cancerol Radiotherapie, 1 Ave Claude Vellefaux, F-75010 Paris, France
[5] Ctr Hosp Univ Lyon Sud, Dept Radiotherapie Oncol, 165 Chemin Grand Revoyet, F-69495 Pierre Benite, France
[6] Univ Lyon, F-69000 Lyon, France
[7] Univ Paris Saclay, Dept Radiotherapie Oncol, Gustave Roussy Canc campus, INSERM,Oncostat U1018, Villejuif, France
[8] Univ Lille, Lille, France
[9] CNRS CRIStAL UMR 9189, Lille, France
来源：
CANCER RADIOTHERAPIE | 2023年 / 27卷 / 6-7期
关键词：
Stereotactic body radiotherapy; Renal cell carcinoma; Primary kidney cancer; RENAL-CELL CARCINOMA; RADIOSURGERY ONCOLOGY CONSORTIUM; POOR SURGICAL CANDIDATES; DOSE-ESCALATION; ABLATIVE RADIOTHERAPY; MANAGEMENT;
D O I：
10.1016/j.canrad.2023.06.022
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The incidence of primary renal cancer is increasing, particularly in elderly patients who may have comorbidities and/or a surgical contraindications. Stereotactic body radiotherapy has primarily been evaluated retrospectively to date. The most commonly used dose schedules are 40 Gy in five fractions, 42 Gy in three fractions, and 26 Gy in one fraction. The results in terms of local control and toxicity are very encouraging. The advantages of stereotactic body radiotherapy compared to thermal ablative treatments are its non-invasive nature, absence of general anesthesia, ability to treat larger lesions, and those close to the renal hilum. Prospective evaluations are still necessary. (c) 2023 Societe franc, aise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：568 / 572
页数：5
相关论文
共 50 条
  • [41] A New Strategy for Metachronous Primary Lung Cancer: Stereotactic Body Radiation Therapy with Concurrent Chemotherapy
    Takeshita, Jumpei
    Masago, Katsuhiro
    Kato, Ryoji
    Otsuka, Kyoko
    Okuda, Chiyuki
    Hata, Akito
    Kaji, Reiko
    Fujita, Shiro
    Takayama, Kenji
    Kokubo, Masaki
    Katakami, Nobuyuki
    ANTICANCER RESEARCH, 2015, 35 (05) : 3103 - 3107
  • [42] Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer
    Toesca, Diego A. S.
    Osmundson, Evan C.
    von Eyben, Rie
    Shaffer, Jenny L.
    Koong, Albert C.
    Chang, Daniel T.
    PRACTICAL RADIATION ONCOLOGY, 2017, 7 (03) : 173 - 182
  • [43] Stereotactic Body Radiation Therapy as a Part of Definitive Treatment for Synchronous Double Primary Lung Cancer
    Shintani, T.
    Takayama, K.
    Kokubo, M.
    Imagumbai, T.
    Kosaka, Y.
    Ueki, N.
    Kimino, G.
    Katakami, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S606 - S606
  • [44] Stereotactic body radiation therapy (SBRT) for the treatment of primary lung cancer in recipients of lung transplant
    Moore, Assaf
    Kramer, Mordechai R.
    Rosengarten, Dror
    Shtraichman, Osnat
    Zer, Alona
    Dudnik, Elizabeth
    Korzets, Yasmin
    Allen, Aaron M.
    RADIOLOGY AND ONCOLOGY, 2020, 54 (02) : 227 - 232
  • [45] Stereotactic body radiation therapy (SBRT) for the treatment of primary breast cancer in patients not undergoing surgery
    Zabrocka, Ewa
    Roberson, John D.
    Noldner, Collin
    Kim, Jinkoo
    Patel, Rushil
    Ryu, Samuel
    Stessin, Alexander
    ADVANCES IN MEDICAL SCIENCES, 2024, 69 (01): : 29 - 35
  • [46] Comparison of stereotactic body radiation therapy versus fractionated radiation therapy for primary liver cancer with portal vein tumor thrombus
    Zhang, Sujing
    He, Li
    Bo, Changwen
    Yang, Shufang
    An, Yonghui
    Li, Na
    Zhao, Yingchun
    Zhao, Liping
    Ma, Wenhua
    Zheng, Zheng
    RADIATION ONCOLOGY, 2021, 16 (01)
  • [47] Comparison of stereotactic body radiation therapy versus fractionated radiation therapy for primary liver cancer with portal vein tumor thrombus
    Sujing Zhang
    Li He
    Changwen Bo
    Shufang Yang
    Yonghui An
    Na Li
    Yingchun Zhao
    Liping Zhao
    Wenhua Ma
    Zheng Zheng
    Radiation Oncology, 16
  • [48] The role of Stereotactic Body Radiation Therapy in Oligometastatic Prostate Cancer
    Munoz Munoz, O.
    Burgueno Caballero, A. M.
    Gomis Selles, E.
    Cabrera Roldan, P.
    Munoz Carmona, D. M.
    Delgado Leon, B. D.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S1167 - S1168
  • [49] Early toxicity with stereotactic body radiation therapy for prostate cancer
    Saavedra Bejarano, J.
    Rubio Jimenez, M.
    Vicente Ruiz, P.
    Ortiz Seidel, M.
    Marquez Garcia-Salazar, M.
    Illescas Vacas, A.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S1688 - S1688
  • [50] Stereotactic body radiation therapy for clinically localized prostate cancer
    Vorobyov, N. A.
    Martynova, N. I.
    Mikhailov, A. V.
    Gutsalo, Yu. V.
    Kubasov, A. V.
    ONKOUROLOGIYA, 2018, 14 (02): : 122 - 129
12345